Ladenburg Thalmann analyst Aydin Huseynov initiated coverage of NeuroBo Pharmaceuticals with a Buy rating and $6 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly